Dr. Wahl’s extensive experience spans almost 20 years in the pharmaceutical and biotech industries across multiple therapeutic areas including oncology, gastrointestinal and neurological, infectious and autoimmune diseases. He has a proven track record in strategy and operations including strong business development experience with M&A, license, co-development and supply agreements. He is also an inventor with more than 150 U.S. and international patents and patent applications.
He joined the company as Chief Business Officer in July 2023 and is responsible for the Business Development and Corporate Development organizations.
Prior to Halozyme, Dr. Wahl most recently served as Corporate Vice President of Strategy and Business Development for Biora Therapeutics, while also providing significant operational guidance on research and development for novel drug device combination products. He previously held the position of Chief Operating Officer at Interface, an early-stage biotech company focused on developing diagnostics and therapeutics based on the human-microbiome interface, and Micropharma Limited. He started his career at Shriners Hospital, Merck and McKinsey and Company.
Dr. Wahl earned Bachelor of Science degrees in accounting and business administration and a Bachelor of Arts degree in biology from Washington and Lee University. He earned his Doctor of Medicine and Master of Business Administration from McGill University.